Factors influencing ovarian cancer survival after chemotherapy.
D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001835:Body Weight; D003520:Cyclophosphamide / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D004715:Endometriosis / Q000188:drug therapy / Q000276:immunology / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D004906:Erythrocyte Count; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008558:Melphalan / Q000627:therapeutic use; D008649:Mesonephroma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D013997:Time Factors
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D008558:Melphalan